The Company made targeted adjustments to the operation mechanism of its own products. It entrusted Shenzhen Kangzhe Medical with the operation of rhBNP and Rhodiola series products, to make full use of its advantages in operation and management, and accelerate the development of two pillar products.
In 2015, the Company's annual profit reached a record high of RMB 80 million.
In 2016, the Company acquired the assets related to IMDUR® product (an international first-line cardiovascular chemical drug) and its brand worldwide (except for the United States). The Company expanded its business layout globally, established and effectively utilized overseas resources to develop the international market for its existing products, which was of great significance for the Company to realize its strategic orientation "from snow-covered plateau to the world".
In 2017, rhBNP was included in Class B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance for the first time. Tibet Rhodiola Pharmaceutical won the "Golden Bull Most Valuable Investment Award" for the first time.
In 2019, Tibet Oxygen Big Health Life Sciences Co., Ltd. was established to deeply explore the therapeutical effect and healthcare of Tibetan medicine, and launch big health products that combines traditional Tibetan medicine/TCM-based health maintenance with modern science and technology, to achieve the goal of "Healthy China" with a big health system.
In 2020, Shanghai SynForce Biotechnology Co., Ltd. was established and a vaccine production base located in Lingang New Area, Shanghai Pilot Free Trade Zone was built. Became a shareholder of Beijing Advanced Medical Technologies, Ltd. Inc. to expand its business to medical device sector.
In 2021, the rhBNP production line was expanded. After being continuously included in Class B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance in 2017, 2019 and 2021, rhBNP achieved a 10-fold increase in sales volume within 6 years. After the new production line was built, the annual output of rhBNP was expected to reach 15 million vials, which played a positive role in the long-term development of the Company while meeting the market demands.
In 2022, the Company registered and incorporated two wholly-owned subsidiaries in Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, namely Tibet Rhodiola Technology Development Co., Ltd. and Tibet Rhodiola Biopharmaceutical Sales Co., Ltd. to adjust the industrial layout structure, achieve the optimal allocation of elements and accelerate the economic operation of the Company.